Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd. has expressed support for the CMS’s proposed adjustments to the Hospital Outpatient Prospective Payment System, which would improve payments for diagnostic radiopharmaceuticals, like their product Illuccix®, in the U.S. These changes would enable separate payments for such pharmaceuticals post-transitional pass-through status, fostering better patient access and supporting ongoing innovation in diagnostic imaging. The final rule is expected to come into effect on January 1, 2025, following a public comment period ending on September 9, 2024.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
